Clinical AI leverage nQ Medical offers AI-driven neurodegenerative monitoring using passive data collection from users’ interaction with common devices, presenting a scalable digital biomarker solution that can be positioned to pharma or contract research organizations for remote patient monitoring and real-world evidence.

Remote recruitment edge Their support for remote, online recruitment in clinical trials can shorten study timelines and improve disease staging, which is attractive to CROs and sponsors seeking faster recruitment and higher-quality trial cohorts.

Therapy integration The Mobile PD Management Platform enables telemetry, titration support, patient engagement, and caregiver observation, offering opportunities to partner with pharmaceutical companies and device manufacturers for combination therapies and digital health endpoints.

Strategic partnerships Existing collaborations with Fleksy and the Davis Phinney Foundation demonstrate a network approach for expanding patient access and real-world data collection, suggesting potential partner channels to scale deployments and broaden market reach.

Market positioning With under $1M in revenue but $4.5M in funding and a small team, there is an opportunity to target niche neurodegenerative programs and early-stage trials where compact, cost-effective digital monitoring platforms can outperform traditional in-clinic assessments.